Who Supplies Metformin to India from TAIWAN

Under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, the import of finished pharmaceutical formulations into India requires registration with the Central Drugs Standard Control Organization (CDSCO). The registration process involves obtaining a No Objection Certificate (NOC) from the CDSCO, which certifies that the imported drug meets the necessary quality, safety, and efficacy standards. The application for registration must include comprehensive documentation, such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining CDSCO registration can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the regulatory review process. For Metformin formulations under HS Code 30049099, specific requirements include providing detailed product information, manufacturing process details, and compliance with Indian Pharmacopoeia standards.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch of imported Metformin formulations requires a Certificate of Analysis (CoA) confirming that the product meets the specified quality parameters. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability under India's climatic conditions. The testing process includes assessments for purity, potency, and dissolution, among other quality attributes. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and additional costs for the importer.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of pharmaceutical formulations. Notably, in April 2025, the CDSCO mandated that import registration and licenses are required for all imported drugs, including finished formulations, to prevent the sale of unapproved or illegal medicines in the Indian market. This regulation emphasizes the need for compliance with the Drugs and Cosmetics Act and Rules. Additionally, in December 2025, the Directorate General of Foreign Trade (DGFT) revised Standard Input Output Norms (SION) A-290, changing the Unit of Measurement (UOM) for Metformin HCL inputs from a ratio-based measure to an absolute quantity per unit of export product. These changes aim to streamline the import process and ensure better quality control of pharmaceutical products entering India.

India imports finished Metformin formulations to meet the growing demand for diabetes management, particularly for patented or branded formulations and specific dosage forms not produced domestically. The domestic pharmaceutical industry has a significant capacity to produce Metformin; however, certain specialized formulations or higher-quality products may necessitate imports. The market size for Metformin formulations in India is substantial, with imports contributing to the overall supply to address the needs of the diabetic population.

The import of Metformin formulations under HS Code 30049099 into India is subject to a Basic Customs Duty (BCD) of 10.00%. Additionally, a Social Welfare Surcharge (SWS) of 10.00% is applied on the BCD, resulting in a total duty of 17.10%. Importers should also consider the applicability of Goods and Services Tax (GST) and any other applicable duties or exemptions based on the specific product and current regulations. It's essential to stay updated with the latest customs notifications and consult with a Customs House Agent (CHA) for accurate duty calculations.

India sources Metformin formulations from Taiwan due to the competitive advantages offered by Taiwanese manufacturers, including compliance with international quality standards, advanced manufacturing technologies, and the ability to produce specialized dosage forms. Taiwan's pharmaceutical industry is known for its high-quality products and adherence to Good Manufacturing Practice (GMP) guidelines, making it a reliable source for Metformin formulations. While other countries like China, Germany, and the United States also supply Metformin formulations to India, Taiwan's unique combination of quality, innovation, and cost-effectiveness positions it favorably in the Indian market.

India imports Metformin formulations from Taiwan due to the high quality and specialized formulations offered by Taiwanese manufacturers. Taiwan's adherence to international quality standards, advanced manufacturing technologies, and the ability to produce specific dosage forms not available domestically make it a preferred source. The demand for such specialized products in India drives the import of Metformin formulations from Taiwan.

When compared to other origins like China, the European Union, and the United States, Taiwan offers a competitive advantage in terms of product quality, regulatory compliance, and cost-effectiveness. Taiwanese manufacturers are known for their stringent quality control measures and compliance with Good Manufacturing Practice (GMP) guidelines, ensuring high-quality products. Additionally, Taiwan's efficient supply chain and favorable trade relations with India